Kaira Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 3 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.00 M
- Revenue Growth 145.08%
- Profit Growth 751.12%
- Ebitda 5918.76%
- Net Worth 37.42%
- Total Assets 37.42%
About Kaira Drugs
Kaira Drugs Private Limited (KDPL) is a Private Limited Indian Non-Government Company incorporated in India on 02 August 2021 (Three years and six months 1 days old ). Its registered office is in Ganjam, Odisha, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.00 M.
Sachindra Patro and Ramyakanta Patro serve as directors at the Company.
Company Details
-
Location
Ganjam, Odisha, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24299OR2021PTC037164
-
Company No.
037164
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
02 Aug 2021
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Cuttack
Industry
Who are the key members and board of directors at Kaira Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sachindra Patro
|
Managing Director | 02-Aug-2021 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Ramyakanta Patro
|
Director | 02-Aug-2021 | Current |
Financial Performance of Kaira Drugs.
Kaira Drugs Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 145.08% increase. The company also saw a substantial improvement in profitability, with a 751.12% increase in profit. The company's net worth Soared by an impressive increase of 37.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kaira Drugs?
Unlock access to Kaira Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹2.00 M
₹0
Charges Breakdown by Lending Institutions
- Indian Overseas Bank : 0.20 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 Feb 2024 | Indian Overseas Bank | ₹2.00 M | Open |
How Many Employees Work at Kaira Drugs?
Kaira Drugs has a workforce of 0 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kaira Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kaira Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.